AI has the potential to save vast amounts of time and money by optimizing pharma supply chain processes, but companies must think about legal risk and liability from all angles, Ewan Townsend, partner at law firm Arnold & Porter, tells the Pink Sheet.
From forecasting the demand for goods to analyzing the efficiency of manufacturing processes, AI has the potential to fine-tune the pharmaceutical supply chain and improve the yield of drugs produced from raw materials.
Although supply chain uses for AI are “less glamorous” than other applications in the pharma space, such as in drug...
Create an account to read this article
Already a subscriber?
Sanofi’s EU regulatory science and policy head draws on a “nightmare” experience with using a generative AI tool to compare versions of the draft EU pharma reform text to explain the benefits and limitations of artificial intelligence tools in regulatory affairs.
A new government-backed initiative is set to explore the use of AI in predicting side effects from drug interactions – a development that could cut costs and late-stage trial failures for pharma companies.
The UK MHRA is looking to support drug sponsors in using in silico data during the drug development process – a move that will reduce the use of animal models.
Clinical trial sponsors could soon benefit from a streamlined clinical trial approval process in Australia, Canada, Singapore, Switzerland and the UK under a new ACCESS Consortium project.
A new 10-year, government-supported R&D program in China will focus on new targets and emerging technologies which can be translated into first-in-class drugs and give birth to top players in the global pharma industry.
The ARPA-H program is making individualized genetic therapies a new research priority, including the “THRIVE” grant program, which will seek genetic platforms beyond AAV and CRISPR, and “GIVE,” which will support bedside manufacturing for RNA therapies.
The FDA cannot “rest on its laurels” when it comes to advancing cell and gene therapy regulatory advances, the acting head of the Office of Therapeutic Products said. Leveraging knowledge across programs could be a key.
